Viking Therapeutics, Inc. (VKTX) Balance Sheet

The reported equity trajectory has been volatile, with equity declining from $946.8M in total assets terms through 2025 before rebounding sharply in 2026Q3. The jump in cash to $677.6M in 2026Q3 from $125.8M in 2026Q2 points to a large financing inflow, which may indicate the company has accessed capital markets after a period of tightening liquidity. Investors should monitor whether this funding is sufficient to support the current quarterly loss run-rate of roughly $183M.

Debt was essentially absent through 2024 and most of 2025, then appeared at $254.7M in the latest quarter, a step change that warrants further investigation into its terms and maturity profile. A D/E of 0.43 is not alarming on its own, but for a company with no reported revenue and negative operating cash flow, any debt service obligation is a claim on a shrinking liquidity base. The debt composition and covenant terms are not provided in the data, so the refinancing risk cannot be fully assessed.

Taken at face value, the current ratio and cash balance indicate ample coverage of current liabilities, which stood at roughly $388.6M of total liabilities. However, cash runway should be judged against the quarterly burn rate rather than the absolute cash figure, and at the reported deficit the buffer equates to only a few quarters of spending. The sharp swing from $125.8M cash a quarter earlier suggests liquidity is being managed through periodic capital raises rather than from internally generated resources.

The growth of the accumulated deficit by roughly $450M in three quarters reflects the scale of recent operating losses and the non-cash stock-based compensation that has risen alongside them. Equity quality is therefore dependent on continued access to external funding, since the book value is a function of capital raised rather than earnings retained. Dilution from equity issuance is a likely consequence of the funding pattern, though the share count data is not provided here to quantify it.